🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Biliary Disease

Mapping Disease Pathways for Biliary Atresia NCT03273049n/a1 site📍 Pittsburgh University of Pittsburgh A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations NCT05503797Phase 270 sites📍 Beverly Hills📍 San Francisco📍 Westwood, Los Angeles Fore Biotherapeutics · Tests: Plixorafenib Personalized Medicine for Advanced Biliary Cancer Patients NCT05615818Phase 369 sites📍 Brussels📍 Brussels📍 Edegem UNICANCER · Tests: Futibatinib, Ivosidenib, Zanidatamab, Trastuzumab, Neratinib Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting NCT07453186NA1 site📍 Esbjerg Esbjerg Hospital - University Hospital of Southern Denmark · Tests: Diagnostic procedures AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis NCT05335603n/a1 site📍 Hvidovre University of Copenhagen A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer NCT07267078Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Tuvonralimab/Iparomlimab combination with GEMOX chemotherapy NGS in Gallbladder Cancer and Response to Treatment NCT05404347n/a1 site📍 Varanasi Banaras Hindu University · Tests: Next generation sequencing Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room NCT07473687n/a1 site📍 Taipei Taipei Veterans General Hospital, Taiwan · Tests: Non-contact rPPG software FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis NCT06286709Phase 25 sites📍 Birmingham📍 London📍 London University of Birmingham · Tests: Faecal Microbiota Transplant, FMT Placebo Prevention of Bile Leakage After Liver Resection in Children NCT07867522NA1 site📍 Moscow Federal Research Institute of Pediatric Hematology, Oncolog… · Tests: prophylactic extrahepatic biliary drainage during liver resection Effect of Geriatric Intervention in Frail Patients with Gastric, Biliary, and Pancreatic Cancer Receiving Palliative Chemotherapy NCT06040801NA1 site📍 Taoyuan Chang Gung Memorial Hospital · Tests: Frailty intervention measures A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA NCT07282353Phase 342 sites📍 Hefei📍 Hefei📍 Hefei Cascade Pharmaceuticals, Inc · Tests: 2mg CS0159, Placebo Efficacy of Fistulotomy for Biliary Cannulation NCT04037007NA1 site📍 Mexico City Coordinación de Investigación en Salud, Mexico · Tests: Fistulotomy - High experienced., Fistulotomy - Low experienced., Conventional (guidewire) cannulation- High experienced… A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) NCT06564623Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients NCT07673861NA1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Marsden360 ctDNA test and GTAB review Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688Phase 1, Phase 211 sites📍 San Antonio📍 Tyler📍 Spokane TiumBio Co., Ltd. · Tests: TU2218 + KEYTRUDA® (Pembrolizumab) Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE) NCT06315179n/a1 site📍 Seattle Seattle Children's Hospital · Tests: Esophagogastroduodenoscopy (EGD) with biopsy, Colonoscopy w/ biopsy Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III) NCT07161869n/a6 sites📍 Rotterdam📍 Amsterdam📍 Groningen Erasmus Medical Center · Tests: Registration of all findings during preoperative Endoscopic Ultrasound Austrian PBC Registry NCT07598669n/a11 sites📍 Klagenfurt📍 Sankt Pölten📍 Salzburg Medical University of Vienna Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia NCT07513038Phase 1, Phase 21 site📍 Boston Boston Children's Hospital · Tests: Indocyanine Green (ICG) One-year Outcomes by Index Treatment in Elderly Patients With Acute Cholecystitis NCT07006298n/a1 site📍 Alicante Instituto de Investigación Sanitaria y Biomédica de Alicante Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma NCT05874414Phase 1, Phase 211 sites📍 Los Angeles📍 Los Angeles📍 Orlando Genfit · Tests: GNS561 + Trametinib Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer NCT07636798Phase 1, Phase 21 site📍 Chengdu West China Hospital · Tests: HAIC Combined Regimen Treatment Group CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers NCT06548412Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Gemcitabine, Cisplatin, Durvalumab, CTX-009 Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in Sohag Locality NCT07885800n/a1 site📍 Sohag Sohag University · Tests: histopathology of gall bladder
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy